Published :
Tables : 50
Figures : 30
Category : Healthcare
No. of Pages : 243
Report Code : HC-1179
MiRNA Sequencing and Assay Market is poised to value USD 645.11 million by 2028 end at a CAGR of 13.3% during the forecast period 2022 to 2028. miRNA sequencing is a high-throughput DNA sequencing which is a parallel, next-generation sequencing technique used for microRNAs. It is different from other forms of RNA sequencing as the input material is augmented for small RNAs. miRNA sequencing permits researchers to understand tissue-specific expression patterns, isoforms of miRNA and disease associations and most importantly, to discover miRNAs that were previously uncharacterized. The articulation of miRNA is primarily related to epithelial-mesenchymal change, BRCA transformations, insusceptible framework, malignant growth immature properties of microorganism in triple-negative bosom disease and androgen receptor articulation. With advancements in computational methodologies and genomics, the market in the Middle East & Africa is projected to soar significantly. The miRNA sequencing approach gives a high-throughput sequencing that proportionate the procedure and simultaneously creating thousands of groupings. This sequencing technique can turn into an integral instrument in the prognostics and diagnostics division. The increasing frequency of development and malignant growth of examination exercises in the hereditary sector, rising demand for financially shrewd genome sequencing procedures are the factors that shall augment the market growth. Very few miRNA therapeutics that can show conceivable results for the vascular ailment, Hepatitis C infection, cardiometabolic illness, fringe blood vessel ailment and other malignancies, are under different clinical preliminaries. These therapeutics have immense potential in preclinical examinations which are foreseen to bolster research and development in upcoming years. The Middle East & Africa is one important region for the miRNA sequencing and assay market. Expansion of government support for genomic research, the proximity of world-class organizations dedicated to hereditary research, high-throughput miRNA examination procedures are some integral factors responsible for the market growth in the region. The increasing demand for miRNA sequencing and extensive hereditary research exercises are poised to significantly augment the market growth in the region. Key market players are Illumina, Inc., Thermo Fisher Scientific, Qiagen, Perkinelmer, Inc., Takara Bio, Inc., New England Biolabs, Inc., Norgen Biotek Corporation, Trilink Biotechnologies, Lexogen, Oxford Nanopore Technologies. miRNA Sequencing and Assay Market Segmentation: By Product Sequencing Consumables Library Preparation Kits By Technology Sequencing by Synthesis Ion Semiconductor Sequencing Sequencing by Oligonucleotide Ligation and Detection Nanopore Sequencing By End User Research and Academic Institutes Contract Research Organizations By Region North America Europe Asia Pacific Middle East & Africa Rest of the World Competitive Landscape: Tier 1 players- established companies in the market with a major market share Tier 2 players Emerging players which are growing rapidly New Entrants FutureWise Key Takeaways: Growth prospects SWOT analysis Key trends Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the miRNA sequencing and assay market by product, by technology, by end user and by region To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) To evaluate and forecast micro-markets and the overall market To predict the market size, in key regions (along with countries)— North America, Asia Pacific, Europe, Middle East & Africa and rest of the world To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions Profiling of companies to evaluate their market shares, strategies, financials and core competencies
miRNA sequencing is a high-throughput DNA sequencing which is a parallel, next-generation sequencing technique used for microRNAs. It is different from other forms of RNA sequencing as the input material is augmented for small RNAs. miRNA sequencing permits researchers to understand tissue-specific expression patterns, isoforms of miRNA and disease associations and most importantly, to discover miRNAs that were previously uncharacterized.
The articulation of miRNA is primarily related to epithelial-mesenchymal change, BRCA transformations, insusceptible framework, malignant growth immature properties of microorganism in triple-negative bosom disease and androgen receptor articulation. With advancements in computational methodologies and genomics, the market in the Middle East & Africa is projected to soar significantly.
The miRNA sequencing approach gives a high-throughput sequencing that proportionate the procedure and simultaneously creating thousands of groupings. This sequencing technique can turn into an integral instrument in the prognostics and diagnostics division. The increasing frequency of development and malignant growth of examination exercises in the hereditary sector, rising demand for financially shrewd genome sequencing procedures are the factors that shall augment the market growth.
Very few miRNA therapeutics that can show conceivable results for the vascular ailment, Hepatitis C infection, cardiometabolic illness, fringe blood vessel ailment and other malignancies, are under different clinical preliminaries. These therapeutics have immense potential in preclinical examinations which are foreseen to bolster research and development in upcoming years.
The Middle East & Africa is one important region for the miRNA sequencing and assay market. Expansion of government support for genomic research, the proximity of world-class organizations dedicated to hereditary research, high-throughput miRNA examination procedures are some integral factors responsible for the market growth in the region. The increasing demand for miRNA sequencing and extensive hereditary research exercises are poised to significantly augment the market growth in the region.
Key market players are Illumina, Inc., Thermo Fisher Scientific, Qiagen, Perkinelmer, Inc., Takara Bio, Inc., New England Biolabs, Inc., Norgen Biotek Corporation, Trilink Biotechnologies, Lexogen, Oxford Nanopore Technologies.
miRNA Sequencing and Assay Market Segmentation:
By Product
By Technology
By End User
By Region
Competitive Landscape:
FutureWise Key Takeaways:
Objectives of the Study:
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. MiRNA Sequencing and Assay Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of MiRNA Sequencing and Assay Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. MiRNA Sequencing and Assay Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. MiRNA Sequencing and Assay Market, By Product Type Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Sequencing Consumables 7.2. Library Preparation Kits 8. MiRNA Sequencing and Assay Market, By Technology Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Sequencing by Synthesis 8.2. Ion Semiconductor Sequencing 8.3. Sequencing by Oligonucleotide Ligation and Detection 8.4. Nanopore Sequencing 9. MiRNA Sequencing and Assay Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Research and Academic Institutes 9.2. Contract Research Organizations 10. North America MiRNA Sequencing and Assay Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2022-2028 11. Latin America MiRNA Sequencing and Assay Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Brazil 11.2.2. Venezuela 11.2.3. Argentina 11.2.4. Rest of Latin America 11.3. Market Size (USD Million) Forecast for Latin America 2022-2028 12. Europe MiRNA Sequencing and Assay Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5. Spain 12.2.6. Russia 12.2.7. Poland 12.2.8. Rest of Europe 12.3. Market Size (USD Million) Forecast for Europe 2022-2028 13. Asia Pacific MiRNA Sequencing and Assay Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Japan 13.2.2. China 13.2.3. India 13.2.4. Australia and New Zealand 13.2.5. ASEAN 13.2.6. Rest of Asia Pacific 13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. GCC 14.2.2. Israel 14.2.3. South Africa 14.2.4. Rest of MEA 14.3. Market Size (USD Million) Forecast for MEA 2022-2028 15. Market Share Analysis and Competitive Landscape 15.1. Global Landscape - Key Players, Revenue and Presence 15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 15.3. Global Emerging Companies 15.4. North America - Market Share Analysis and Key Regional Players 15.5. Europe - Market Share Analysis and Key Regional Players 15.6. Asia Pacific - Market Share Analysis and Key Regional Players 15.7. Global Key Player - Growth Matrix 16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 16.1. Illumina, Inc. 16.1.1. Company Overview 16.1.2. Product Portfolio 16.1.3. SWOT Analysis 16.1.4. Financial Overview 16.1.5. Strategic Overview 16.2. Thermo Fisher Scientific 16.2.1. Company Overview 16.2.2. Product Portfolio 16.2.3. SWOT Analysis 16.2.4. Financial Overview 16.2.5. Strategic Overview 16.3. Qiagen 16.3.1. Company Overview 16.3.2. Product Portfolio 16.3.3. SWOT Analysis 16.3.4. Financial Overview 16.3.5. Strategic Overview 16.4. Perkinelmer, Inc. 16.4.1. Company Overview 16.4.2. Product Portfolio 16.4.3. SWOT Analysis 16.4.4. Financial Overview 16.4.5. Strategic Overview 16.5. Takara Bio, Inc. 16.5.1. Company Overview 16.5.2. Product Portfolio 16.5.3. SWOT Analysis 16.5.4. Financial Overview 16.5.5. Strategic Overview 16.6. New England Biolabs, Inc. 16.6.1. Company Overview 16.6.2. Product Portfolio 16.6.3. SWOT Analysis 16.6.4. Financial Overview 16.6.5. Strategic Overview 16.7. Norgen Biotek Corporation 16.7.1. Company Overview 16.7.2. Product Portfolio 16.7.3. SWOT Analysis 16.7.4. Financial Overview 16.7.5. Strategic Overview 16.8. Trilink Biotechnologies 16.8.1. Company Overview 16.8.2. Product Portfolio 16.8.3. SWOT Analysis 16.8.4. Financial Overview 16.8.5. Strategic Overview 16.9. Lexogen 16.9.1. Company Overview 16.9.2. Product Portfolio 16.9.3. SWOT Analysis 16.9.4. Financial Overview 16.9.5. Strategic Overview 16.10. Oxford Nanopore Technologies 16.10.1. Company Overview 16.10.2. Product Portfolio 16.10.3. SWOT Analysis 16.10.4. Financial Overview 16.10.5. Strategic Overview 17. Pre and Post COVID-19 Impact 17.1. Positive influence on the healthcare industry 17.2. The financial disruption of the manufacturing sector 17.3. Impact of COVID-19 on emerging companies 17.4. Significant mandates in the regulations initiated by healthcare administrations 17.5. The overall economic slowdown of the developing and developed nations 18. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders
2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study
3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights
4. MiRNA Sequencing and Assay Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of MiRNA Sequencing and Assay Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. MiRNA Sequencing and Assay Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. MiRNA Sequencing and Assay Market, By Product Type Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Sequencing Consumables 7.2. Library Preparation Kits
8. MiRNA Sequencing and Assay Market, By Technology Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Sequencing by Synthesis 8.2. Ion Semiconductor Sequencing 8.3. Sequencing by Oligonucleotide Ligation and Detection 8.4. Nanopore Sequencing
9. MiRNA Sequencing and Assay Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Research and Academic Institutes 9.2. Contract Research Organizations
10. North America MiRNA Sequencing and Assay Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2022-2028
11. Latin America MiRNA Sequencing and Assay Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Brazil 11.2.2. Venezuela 11.2.3. Argentina 11.2.4. Rest of Latin America 11.3. Market Size (USD Million) Forecast for Latin America 2022-2028
12. Europe MiRNA Sequencing and Assay Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5. Spain 12.2.6. Russia 12.2.7. Poland 12.2.8. Rest of Europe 12.3. Market Size (USD Million) Forecast for Europe 2022-2028
13. Asia Pacific MiRNA Sequencing and Assay Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Japan 13.2.2. China 13.2.3. India 13.2.4. Australia and New Zealand 13.2.5. ASEAN 13.2.6. Rest of Asia Pacific 13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. GCC 14.2.2. Israel 14.2.3. South Africa 14.2.4. Rest of MEA 14.3. Market Size (USD Million) Forecast for MEA 2022-2028
15. Market Share Analysis and Competitive Landscape 15.1. Global Landscape - Key Players, Revenue and Presence 15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 15.3. Global Emerging Companies 15.4. North America - Market Share Analysis and Key Regional Players 15.5. Europe - Market Share Analysis and Key Regional Players 15.6. Asia Pacific - Market Share Analysis and Key Regional Players 15.7. Global Key Player - Growth Matrix
16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 16.1. Illumina, Inc. 16.1.1. Company Overview 16.1.2. Product Portfolio 16.1.3. SWOT Analysis 16.1.4. Financial Overview 16.1.5. Strategic Overview 16.2. Thermo Fisher Scientific 16.2.1. Company Overview 16.2.2. Product Portfolio 16.2.3. SWOT Analysis 16.2.4. Financial Overview 16.2.5. Strategic Overview 16.3. Qiagen 16.3.1. Company Overview 16.3.2. Product Portfolio 16.3.3. SWOT Analysis 16.3.4. Financial Overview 16.3.5. Strategic Overview 16.4. Perkinelmer, Inc. 16.4.1. Company Overview 16.4.2. Product Portfolio 16.4.3. SWOT Analysis 16.4.4. Financial Overview 16.4.5. Strategic Overview 16.5. Takara Bio, Inc. 16.5.1. Company Overview 16.5.2. Product Portfolio 16.5.3. SWOT Analysis 16.5.4. Financial Overview 16.5.5. Strategic Overview 16.6. New England Biolabs, Inc. 16.6.1. Company Overview 16.6.2. Product Portfolio 16.6.3. SWOT Analysis 16.6.4. Financial Overview 16.6.5. Strategic Overview 16.7. Norgen Biotek Corporation 16.7.1. Company Overview 16.7.2. Product Portfolio 16.7.3. SWOT Analysis 16.7.4. Financial Overview 16.7.5. Strategic Overview 16.8. Trilink Biotechnologies 16.8.1. Company Overview 16.8.2. Product Portfolio 16.8.3. SWOT Analysis 16.8.4. Financial Overview 16.8.5. Strategic Overview 16.9. Lexogen 16.9.1. Company Overview 16.9.2. Product Portfolio 16.9.3. SWOT Analysis 16.9.4. Financial Overview 16.9.5. Strategic Overview 16.10. Oxford Nanopore Technologies 16.10.1. Company Overview 16.10.2. Product Portfolio 16.10.3. SWOT Analysis 16.10.4. Financial Overview 16.10.5. Strategic Overview
17. Pre and Post COVID-19 Impact 17.1. Positive influence on the healthcare industry 17.2. The financial disruption of the manufacturing sector 17.3. Impact of COVID-19 on emerging companies 17.4. Significant mandates in the regulations initiated by healthcare administrations 17.5. The overall economic slowdown of the developing and developed nations
18. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics